Connect with us

Hi, what are you looking for?

Courts

Cannabis Commission can proceed as companies continue to poke at scoring system

Multiple companies asked a Montgomery court to halt the Alabama Medical Cannabis Commission once again.

Gavel of judge lying on green leaves of marijuana closeup. Illegal drug production and distribution of drugs concept
STOCK

Multiple companies asked a Montgomery court to halt the Alabama Medical Cannabis Commission once again due to the commission’s continued use of third-party scoring.

Judge James Anderson denied that request Monday, allowing the commission to proceed with its new procedures and timelines. 

However, Anderson will still be hearing a motion on the use of the scores.

But a request by Specialty Medical Products of Alabama for a preliminary injunction and declaration that the scoring system cannot be used will move forward.

Lawyers for the company, as well as main litigant Alabama Always, brought witnesses to combat the scoring system. 

Alabama Always brought Greg Gerdeman, chief scientific officer for the company, testified that scores were too subjective to be relied on.

Ray French, CEO of Specialty Medical Products, pointed to widely varying scores between two evaluators for the company.

Advertisement. Scroll to continue reading.

Counsel for AMCC continued to argue the scores are allowable as a tool to help commissioners choose applicants.

Jacob Holmes is a reporter at the Alabama Political Reporter. You can reach him at [email protected]

More from APR

Featured Opinion

To make sense of Alabama lawmakers forcing hundreds of businesses to close, just follow the money.

Featured Opinion

The Alabama Medical Cannabis Commission did Thursday what it's done best in its four-plus years of existence: Got more taxpayer money for lawyers.

Opinion

So many of us come home carrying invisible wounds — anxiety, chronic pain, and PTSD that do not just disappear when we hang up...

Courts

Parents demand court intervention as Alabama Medical Cannabis Commission delays treatment access despite clear legal mandates.